Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  Lewis, Myles J ^a   D'Cruz, D ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cell adhesion molecules; Murine lupus; Mycophenolate mofetil; Systemic lupus erythematosus

Indexed keywords

CELL ADHESION MOLECULE; INOSINATE DEHYDROGENASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRODRUG; VASCULAR CELL ADHESION MOLECULE 1;

CELL ADHESION; CELL SURFACE; ENDOTHELIUM CELL; HUMAN; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 16244367139     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2113oa     Document Type: Review

References (83)

1. Springer AS. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
2. Sfikakis PP, Tsokos GC. Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Clinical & Experimental Rheumatology 1995; 13: 763-777.
3. McMurray RW. Adhesion molecules in autoimmune disease. Seminars in Arthritis and Rheumatism 1996; 25: 215-233.
4. Janssen BA, Luqmani RA, Gordon C et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. British Journal of Rheumatology 1994; 33: 1112-1116.
5. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994; 97: 439-444.
6. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
7. Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen induced cytokines. Immunopharmacology 1993; 26: 11-20.
8. Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. American Journal of Kidney Diseases 2002; 40: 447-457.
9. Adu D. The evidence base for the treatment of lupus nephritis in the new millennium. Nephrology Dialysis Transplantation 2001; 16: 1536-1538.
10. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney International 1997; 51: 1583-1589.
11. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. Journal of the American Society of Nephrology 1998; 9: 1407-1415.
12. Jonsson CA, Erlandsson M, Svensson L, Molne J, Carlsten H. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice. Cellular Immunology 1999; 197: 136-144.
13. Jonsson CA, Svensson L, Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clinical & Experimental Immunology 1999; 116: 534-541.
14. Yu CC, Yang CW, Wu MS et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. Journal of Laboratory & Clinical Medicine 2001; 138: 69-77.
15. Zoja C, Benigni A, Noris M et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney International 2001; 60: 653-663
16. Jonsson CA, Carlsten H. Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice. Clinical & Experimental Immunology 2001; 124: 486-491.
17. Lui SL, Tsang R, Wong D et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11: 411-418.
18. Ramos MA, Pinera C, Cibrian E et al. Effects of mycophenolate mofetil in the development of systemic lupus erythematosus in (NZB × NZW) F1 mice. Transplantation Proceedings 2001; 33: 3316-3317.
19. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis & Rheumatism 1994; 37: 376-383.
20. Pallis M, Robson DK, Haskard DO, Powell RJ. Distribution of cell adhesion molecules in skeletal muscle from patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 1993; 52: 667-671.
21. Lhotta K, Neumayer HP, Joannidis M, Geissler D, Konig P. Renal expression of intercellular adhesion molecule-1 in different forms of glomerulonephritis. Clinical Science 1991; 81: 477-481.
22. Daniel L, Sichez H, Giorgi R et al. Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney International 2001; 60: 2215-2221.
23. Bruijn JA, Dinklo NJ. Distinct patterns of expression of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial- leukocyte adhesion molecule-1 in renal disease. Laboratory Investigation 1993; 69: 329-335.
24. Takeuchi T, Amano K, Sekine H, Koide J, Abe T. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. Journal of Clinical Investigation 1993; 92: 3008-3016.
25. Faas MM, Bakker WW, Valkhof N, van der Horst MC, Schuiling GA. Reproductive condition and the low-dose endotoxin-induced inflammatory response in rats: glomerular influx of inflammatory cells and expression of adhesion molecules. Biology of Reproduction 1997; 56: 1400-1406.
26. Winkler M, Kemp B, Hauptmann S, Rath W. Parturition: steroids, prostaglandin E2, and expression of adhesion molecules by endothelial cells. Obstetrics & Gynaecology 1997; 89: 398-402.
27. Chen W, Lee JY, Hsieh WC. Effects of dexamethasone and sex hormones on cytokine-induced cellular adhesion molecule expression in human endothelial cells. European Journal of Dermatology 2002; 12: 445-448.
28. Lai KN, Leung JC, Lai KB, Wong KC, Lai CK. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Clinical Immunology & Immunopathology 1996; 81: 229-238.
29. Haskard DO, Cavender D, Maliakkal D, Ziff M. T-cell adhesion to endothelial cells in systemic lupus erythematosus. Rheumatology International 1989; 9: 33-37.
30. Wuthrich RP. Vascular cell adhesion molecule-1 (VCAM-1) expression in murine lupus nephritis. Kidney International 1992; 42: 903-914.
31. Wuthrich RP, Jevnikar AM, Takei F, Glimcher LH, Kelley VE. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. American Journal of Pathology 1990; 136: 441-450.
32. McHale JF, Harari OA, Marshall D, Haskard DO. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol 1999; 163: 3993-4000.
33. Zameer A, Hoffman SA. Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice. J Neuroimmunol 2003; 142: 67-74.
34. Marshall D, Dangerfield JP, Bhatia VK, Larbi KY, Nourshargh S, Haskard DO. MRL/lpr lupus-prone mice show exaggerated ICAM-1-dependent leucocyte adhesion and transendothelial migration in response to TNF-alpha. Rheumatology (Oxford) 2003; 42: 929-934.
35. Diaz Gallo C, Jevnikar AM, Brennan DC, Florquin S, Pacheco-Silva A, Kelley VR. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney International 1992; 42: 851-859.
36. Harari OA, Marshall D, McHale JF, Ahmed S, Haskard DO. Limited endothelial E- and P-selectin expression in MRL/lpr lupus-prone mice. Rheumatology 2001; 40: 889-895.
37. Argenbright L, Barton R. Interactions of leukocyte integrins with interceullular adhesion molecule 1 in the production of inflammatory vascular injury in vivo: the Shwartzman phenomenon revisited. Journal of Clinical Investigation 1992; 89: 259-273.
38. Kawasaki K, Yaoita E, Yamamoto T, Tamatani T, Miyasaka M, Kihara I. Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescenteric glomerulonephritis. Journal of Immunology 1993; 150: 1074-1083.
39. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clinical Immunology & Immunopathology. 1994; 72: 198-203.
40. Kevil CG, Hicks MJ, He X et al. Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. Am J Pathol 2004; 165: 609-616.
41. Bullard DC, King PD, Hicks MJ, Dupont B, Beaudet AL, Elkon KB. Intercellular adhesion molecule-1 deficiency prolongs survival and protects against the development of pulmonary inflammation during murine lupus. J Immunol 1997; 159: 2058-2067.
42. Lloyd CM, Gonzalo JA, Salant DJ, Just J, Gutierrez-Ramos JC. Intercellular adhesion molecule-1 deficiency prolongs survival and protects against the development of pulmonary inflammation during murine lupus. J Clin Invest 1997; 100: 963-971.
43. Kootstra CJ, Van Der Giezen DM, Van Krieken JH, De Heer E, Bruijn JA. Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies. Clin Exp Immunol 1997; 108: 324-332.
44. Hickey MJ, Bullard DC, Issekutz A, James WG. Leukocyte-endothelial cell interactions are enhanced in dermal postcapillary venules of MRL/fas(lpr) (lupus prone) mice: roles of P- and E-selectin. Journal of Immunology 2002; 168: 4728-4736.
45. James WG, Bullard DC, Hickey MJ. Critical role of the alpha 4 integrin/VCAM-1 pathway in cerebral leukocyte trafficking in lupus-prone MRL/fas(lpr) mice. Journal of Immunology 2003; 170: 520-527.
46. Rosenkranz AR, Mendrick DL, Cotran RS, Mayadas TN. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 1999; 103: 649-659.
47. lpr mice. FASEB J 1999; 13: A855.
48. Tulek N, Aydintug O, Ozoran K et al. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus. Clinical Rheumatology 1996; 15: 47-50.
49. Sfikakis PP, Charalambopoulos D, Vayiopoulos G, Oglesby R, Sfikakis P, Tsokos GC. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clinical & Experimental Rheumatology 1994; 12: 5-9.
50. Machold KP, Kiener HP, Graninger W, Graninger WB. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clinical immunology & Immunopathology 1993; 68: 74-78.
51. Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus. Arthritis & Rheumatism 1993; 36: 519-527.
52. Kling E, Bieg S, Boehme M, Scherbaum WA. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. Clinical Investigator 1993; 71: 299-304.
53. Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. J Rheumatol 2003; 30: 2133-2139.
54. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clinical & Experimental Immunology 1993; 92: 412-418.
55. Zaccagni H, Fried J, Cornell J, Padilla P, Brey RL. Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Front Biosci 2004; 9: 1654-1659.
56. Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 1998; 7: 347-354.
57. Kaplanski G, Cacoub P, Farnarier C et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome. Arthritis & Rheumatism 2000; 43: 55-64.
58. Ho CY, Wong CK, Li EK, Tam LS, Lam CWK. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology 2003; 42: 117-122.
59. Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clinical & Experimental Rheumatology 2002; 20: 403-406.
60. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. Journal of Rheumatology 1993; 20: 809-814.
61. Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000; 9: 614-621.
62. Dunlop LC, Skinner MP, Bendall LJ et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. Journal of Experimental Medicine 1992; 175: 1147-1150.
63. Gearing AJ, Newman W. Circulating adhesion molecules in disease today. Immunology Today 1993; 14: 506-512.
64. Takahashi S, Araki K, Araki M et al. Suppression of experimental lupus nephritis by aberrant expression of the soluble E-selectin gene. Pathology International 2002; 52: 175-180.
65. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25(3 Suppl. 2): 67-70.
66. Laurent AF, Dumont S, Poindron P, Muller CD. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Experimental Hematology 1996; 24: 59-67.
67. Blaheta RA, Leckel K, Wittig B et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transplant Immunology 1998; 6: 251-259.
68. Blaheta RA, Leckel K, Wittig B et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999; 31: 1250-1252.
69. Hauser IA, Johnson DR, Thevenod F, Goppelt-Strube M. Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro. British Journal of Pharmacology 1997; 122: 1315-1322.
70. Kornfeld R, Kornfeld S. Structure of glycoproteins and their oligosaccharide units. In Lennarz WJ Ed. Biochemistry glycoproteins and proteoglycans. Plenum, New York, 1980.
71. Jepson S, Brogan IJ, Stoddart RW, Hutchinson IV. Mycophenolic acid does not inhibit protein glycosylation in T lymphocytes. Transplant Immunology 2000; 8: 169-175.
72. Bertalanffy P, Dubsky P, Wolner E, Weigel G. Alterations of endothelial nucleotide levels by mycophenolic acid result in changes of membrane glycosylation and E-selectin expression. Clinical Chemistry & Laboratory Medicine 1999; 37: 259-264.
73. Valentin JF, Bruijn JA, Paul LC. Donor treatment with mycophenolate mofetil: protection against ischemia-reperfusion injury in the rat. Transplantation 2000; 69: 344-350.
74. Raab M, Daxecker H, Karimi A et al. In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clinica Chimica Acta 2001; 310: 89-98.
75. Weigel G, Bertalanffy P, Dubsky P, Griesmacher A, Wolner E. Mycophenolic acid influences T helper 2 (Th2) cytokine induced expression of intercellular cell adhesion molecule-1 (ICAM-1) on human endothelial cells. Clinical Chemistry & Laboratory Medicine 1999; 37: 253-257.
76. Weigel G, Bertalanffy P, Wolner E. Depletion of intracellular GTP results in nuclear factor-kappaB activation and intercellular adhesion molecule-1 expression in human endothelial cells. Molecular Pharmacology 2002; 62: 453-462.
77. Raab M, Daxecker H, Pavlovic V, Griesmacher A, Mueller MM. Quantification of the influence of mycophenolic acid on the release of endothelial adhesion molecules. Clinica Chimica Acta 2002; 320: 89-94.
78. Heemann U, Azuma H, Hamar P, Schmid C, Tilney N, Philipp T. Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transplant Immunology 1996; 4: 64-67.
79. Wang W, Tong MKH, Lee SH, Chan L. Mycophenolate mofetil protects against renal ischemia/reperfusion injury by inhibiting osteopontin and ICAM-1 expression. Transplantation 1999; 67: S37.
80. McMurray RW, Elbourne KB, Lagoo A, Lal S. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus. J Rheum 1998; 25: 2364-2370.
81. Li LS, Liu ZH, Hong Z, Hu WX. Mycophenolate mofetil showed inhibitory effect on VCAM expression during successful treatment of diffuse proliferative lupus nephritis (SLE-DPGN) with vascular lesions. Journal of the American Society of Nephrologists 1998; 9: 153A.
82. Mason LJ, Isenberg DA. Immunopathogenesis of SLE. Baillière's Clinical Rheumatology 1998; 12: 385-403.
83. Kavanaugh AF, Davis LS, Nichols LA et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37: 992-999.